You are here: Industry Insights > Cardiovascular Diseases

News List

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study Biotech Newswire
August 28, 2024
Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.
Research Progress on the Pharmacological Effects of Salvianolic Acid B in Cardiovascular Diseases Xiaomichong
July 04, 2024
Sal B is a water-soluble component extracted from Danshen (Salvia miltiorrhiza). It is a phenolic acid compound formed by the condensation of 3 molecules of danshensu and 1 molecule of caffeic acid.
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company pharmafocusasia
December 24, 2018
Windtree Therapeutics, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and CVie Investments Limited (CVie).....